Clients & Partners
From idea to market
The best medtech founders don't need advice delivered in a deck. They need operators who'll build the regulatory file, write the pitch, run the interviews, and stay on the journey.
Solentropy is structured as a team of operators – not a roster of part-time advisors. When we engage, we embed in your systems, attend your meetings, and carry the work forward between them.
Our people have clinical credentials, regulatory fluency, and the commercial discipline to build a defensible business. We've led programmes from pre-seed through TGA registration.
The methodology is stage-appropriate. Pre-seed velocity early; scaled rigour later. Every engagement concludes with handover – your knowledge, your systems, your relationships, all retained.
Built on a full-stack medtech consultancy — ten disciplines, one operating team. The wheel below is the depth behind the platforms.
Define what to build. Real insight from real stakeholders — from primary research, not assumptions.
+Structured roadmap. 8 stages, gate to gate, TRL-aligned — from Proof of Principle to In-Market.
+Evidence & payer pathway. Hidden payors found. KOLs as adoption drivers. Health economics baked in early.
+Global approval strategy. Class I to Class III pathway scoping with a clear and achievable submission path.
+Clinical validation. True KOLs, engaged from PoC. Multi-disciplinary advisors built early — not bolted on after launch.
+ISO 13485 compliant, ISO 14971-aligned. Fit-for-purpose QMS, expanded with other standards as the product demands — universal infrastructure for global submissions.
+To market. Capital and growth, integrated. Grants, investor networks, financial models, and senior commercial leadership — all aligned.
+Execution and delivery. One workflow system manages the work, one record system holds the controlled documents. Full traceability end to end.
+Intelligent ops & analytics. AI-powered operational leverage — sales cycle to board reporting, end to end.
+Investor Ready. Bottom-up, TRL-aligned, cash-flow positive — models you can poke.
+From feasibility to in-market — with KOLs and health economics built in early.
KOLs from day one. Health economics baked in, not bolted on.
The same journey, expressed in TRL terms.
Solentropy's proprietary AI research platform for MedTech. Ingests KOL interviews, journals, regulatory guidance, and market intel. Builds a searchable database that grows with the project — current and connected from day one.
"A living intelligence layer for your MedTech project — research, compliance, and market insights, current and connected."
Built for regulated medical software — ready for global approval, secure by design. Onboard new device programs faster, on a platform that evolves from PoC to commercial deployment.
Onboard new device programs faster — on one evolving platform.
Breath-based ketone monitor. Pre-seed AU medtech partnered with ANU sensor research. Solentropy led PMF research (28 stakeholder interviews), financial modelling through FY31, and the current seed raise.
Wearable ECG device for epileptic seizure prediction. Japan's Ministry of Health Fast-Track priority. Solentropy supports user research and design input as the product prepares for international markets.
Solentropy's proprietary AI research platform for MedTech — a living intelligence layer that ingests KOL interviews, journals, regulatory guidance, and market intel. Embedded across engagements, or standalone.
Four research streams flow into sAibr. sAibr synthesises them into structured needs, requirements, and design inputs — each step traceable back to the source. The fourth step is the gate where commercial and regulatory strategy get signed off.
Most MedTech consultancies sequence development and commercialisation — first you build, then you sell. We integrate them from day one. Three workstreams running in parallel, gated together, signed off together.
Solving the chaos of MedTech commercialisation.
From idea to market —
one integrated team.
Paul founded Solentropy in 2018 to do medtech commercialisation differently — as an operating partner inside the venture, not an advisor on the outside. He has spent his career taking medical technologies from early concept through development, regulatory strategy, and capital raising to market.
His track record includes guiding Microbio from TRL 2 to market, raising Seed and Series A investment and installing the corporate leadership to position the company for Series B. He has also supported AdraCard in securing a \ CRC-P grant and implementing a drug-device combination QMS.
Paul has been an active member of the BioMelbourne Network for over a decade and has contributed to the medtech sector as a mentor, judge and programme committee member for initiatives including the BridgeTech Program and AusBiotech. He holds an honours degree in Applied Science and is a Member of the Australian Institute of Company Directors.
Most useful engagements start with a conversation. We're happy to run a no-obligation discovery call – 30 minutes, founders only, no deck.